Location:
Florida Association of Nurse Practitioners
PO Box 602
Lake Helen, FL 32744
Confirmed Time: 6:00 PM – 7:00 PM
Meeting Date: 18-Jun-25
Faculty
James Ellison MD, MPH
Program Chair
Kelly G Knupp, MD MSCS FAES
Professor of Pediatrics and Neurology
University of Colorado, Anschutz Medical Campus
Aurora, CO
Faculty
Paul Schulz, MD
Black Nurses Association of Greater Houston
6436 Fannin St
Houston, TX 77030
Joseph E. Sullivan, MD, FAES Director
Pediatric Epilepsy Center Pediatric
Neurologist UCSF Benioff Children's Hospital
San Francisco, CA
Katherine Nickels, MD, FAAN, FAES
Associate Professor, Neurology
EEG Lab Director
Child and Adolescent Neurology Residency Recruitment Chair
Mayo Clinic
Rochester, MN
PROGRAM OVERVIEW
In this interactive grand rounds program, we will provide instruction on screening, diagnosing, and staging of mild cognitive impairment and Alzheimer’s disease. The lecture and case-based scenarios will educate participants on the appropriate use of disease-modifying therapy, assessing and managing adverse events associated with these therapies, and implementing tools to solve issues with access to therapy. Finally, the faculty will discuss shared decision-making practices and multidisciplinary care as essential elements toward successful treatment of these patients.
TARGET AUDIENCE
This activity is designed to meet the educational needs of healthcare providers involved in the diagnosis and continued care of patients with Alzheimer’s disease, including primary care physicians, neurologists, geriatricians, psychiatrists, nurses, nurse practitioners, physician assistants, and other multidisciplinary team members. Given the coordinated effort required for diagnosis and management of AD patients, it is important to reach both community healthcare providers and specialists. Program activities have been designed in a manner to enable learners to choose programming most relevant to their professional needs.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Integrate evidence-based pathways for screening, diagnosing, and staging MCI and AD
- Appraise clinical practice recommendations informing use of DMTs for AD and identifying those who qualify for treatment based on available clinical data
- Assess and manage potential adverse events associated with DMTs for AD using a multidisciplinary approach
- Develop practice protocols to improve access to DMTs for AD
- Apply best practices for shared decision making when discussing DMT treatment for AD, including discussions of treatment benefits, risks, and what to expect with therapy
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
